Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

0.4240
-0.0149-3.39%
Post-market: 0.42990.0059+1.39%18:05 EDT
Volume:264.85K
Turnover:113.10K
Market Cap:8.26M
PE:-0.04
High:0.4415
Open:0.4371
Low:0.4107
Close:0.4389
52wk High:15.75
52wk Low:0.1614
Shares:19.48M
Float Shares:17.03M
Volume Ratio:0.56
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5973
EPS(LYR):-28.4188
ROE:-1371.64%
ROA:-84.57%
PB:0.71
PE(LYR):-0.01

Loading ...

Moleculin Biotech CEO Klemp to Speak at Maxim Growth Summit Oncology Panel

Reuters
·
Oct 07

Analysts Are Bullish on These NA Stocks: Moleculin Biotech (MBRX), Alphabet Class A (GOOGL)

TIPRANKS
·
Oct 01

Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial

TIPRANKS
·
Sep 29

Moleculin Biotech Completes Part a Enrollment in Phase 2/3 Miracle Trial for Relapsed or Refractory AML

Reuters
·
Sep 29

Moleculin Biotech Completes Enrollment in Part a of Phase 2/3 R/R Aml Miracle Trial, Keeping Program on Track for Q1 2027 Data Readout

THOMSON REUTERS
·
Sep 29

Moleculin Biotech announces publication of analysis of Annamycin in Frontiers

TIPRANKS
·
Sep 28

Moleculin Reports Pooled Analysis Shows no Cardiotoxicity Signal for Annamycin in Five Trials

Reuters
·
Sep 28

Moleculin Says Annamycin Preclinical Data Show CD8+ T Cell-Mediated Activity in Pancreatic Cancer Models

Reuters
·
Sep 26

Moleculin Biotech Wins Mexican Patent for Lung-Targeted Liposomal Annamycin Through 2040

Reuters
·
Sep 23

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

THOMSON REUTERS
·
Sep 23

H.C. Wainwright Sticks to Their Buy Rating for Moleculin Biotech (MBRX)

TIPRANKS
·
Sep 22

Moleculin Biotech Faces Nasdaq Delisting Risk After Notice

TIPRANKS
·
Sep 19

Moleculin Biotech Risks NASDAQ Delisting After Shares Stay Below $1 Bid Threshold

Reuters
·
Sep 19

Moleculin Biotech Says AACR Pancreatic Cancer Conference Features New Annamycin Trial Data

Reuters
·
Sep 14

Moleculin Biotech Highlights Interim Phase 3 AML Data for Annamycin Showing 36% CR, 54% CRc in Pooled Arms

Reuters
·
Sep 01

Moleculin Biotech Updates Investors with New Presentation

TIPRANKS
·
Sep 01

Moleculin Biotech, Inc. : H.c. Wainwright Cuts Target Price to $3 from $22

THOMSON REUTERS
·
Aug 28

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Reuters
·
Aug 28

Moleculin Highlights Interim Data from Pivotal Miracle Phase 2/3 Annamycin Trial in Relapsed/refractory AML

Reuters
·
Aug 27

Moleculin Biotech Announces Annual Shareholder Meeting

Reuters
·
Aug 25